BioTrinity 2026 - Catalysing Growth in the Life Science Industry

We're proud to sponsor BioTrinity 2026, marking 20 years of catalysing growth in life sciences. A two-day event recognised for fostering meaningful collaboration, investment, and scientific progress bringing together a mix of innovators and decision makers for knowledge sharing, partnering and strategic discussion.

Each year, OBN BioTrinity attracts over 850 participants from across the life sciences landscape, including:

• Academic researchers and scientific founders
• Early stage and scaling R&D organisations
• Venture investors, funds and corporate venture arms
• Major pharmaceutical and biotech organisations
• Charities, research institutions and translational bodies
• Government and regulatory representatives
• Specialist advisory firms and industry partners

What’s New in 2026

The 2026 programme introduces several enhancements designed to spotlight innovation and deepen opportunities for connection:

•    Expanded R&D Showcase: Around 160 scientific and commercial updates will be presented, organised by development stage—from academic discovery through to Pre Seed, Seed, Series A and Series B. Marks & Clerk are sponsoring a seed stage presentation on 15 April at 10am. (add link)

•    International Growth Focus: A dedicated day of sessions exploring global markets, helping attendees understand emerging opportunities and expansion pathways.

•    Founder Match Making Lunch: A new facilitated networking format enabling early stage CEOs and founders to meet experts who can provide practical guidance, strategic insight and specialist support.

•    Big Pharma Spotlight: A focused session offering insights from major pharmaceutical companies on partnering priorities and emerging areas of interest.

•    Alternative Funding Pathways: Discussions aimed at helping innovators access non traditional and diversified funding routes to support long term development.

Sponsorship - Supporting Seed‑Stage Innovation

•    Seed stage - Session 4
•    Wednesday 15 April
•    10-11.10am

Marks & Clerk is proud to sponsor and support the Seed Stage R&D Presentations: Session 4 at BioTrinity 2026, taking place on Wednesday, 15 April 2026. The session will be hosted by Roona Deb and also attended by Will Arends and Sophie Topham.

As long‑standing partners of the life sciences innovation community, we are delighted to play a role in showcasing emerging companies, breakthrough science, and the next generation of translational research. BioTrinity provides a platform where early‑stage innovators connect with investors, industry leaders and expert advisors.

Seed Stage R&D Presentations: Session 4 hosted by Roona Deb will feature a group of founders, researchers and scientific entrepreneurs who are shaping the future of healthcare, biotechnology and deep science innovation and include:

• Anaid Benitez - Stratisal
• Ahmet Berkyurek – Cambridge Medixine Ltd
• Sarah Cole - Iscarna
• Michael Dalrymple - Idxsense
• Nataly Hastings – Cellestial Health Ltd
• Aleck Jones – Kindling Bio
• Alastair Monteith‑Hodge FRSA FCIM – PreQlinic Ltd
• Helen Philippou – Clotprotect Therapeutics
• Allart Stoop – Danu Therapeutics
• Thomas Tran – Aceso Therapeutics
• Thomas Weaver – Elijo BioTherapeutics

Each presenter brings forward early‑stage research with the potential to create meaningful impact across the life sciences sector.

Full event details are available on the here